Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (7)
Language
- English (7)
Keywords
- osteogenesis (2)
- CYP24A1 (1)
- ECM remodeling (1)
- MSC (1)
- MSCs (1)
- SIRT1 (1)
- VDR (1)
- adipogenic differentiation (1)
- adult stem cells (1)
- apatite nanoparticles (1)
- bone marrow mesenchymal stromal cells (BM-MSCs) (1)
- bone marrow stromal cells (1)
- bone metastasis (1)
- bone regeneration (1)
- cartilage regeneration (1)
- cell-based therapies (1)
- cellular origin (1)
- chondrogenesis (1)
- collagen (1)
- extracellular vesicles (1)
- femoral head (1)
- human mesenchymal stem cell (1)
- iliac crest (1)
- knee joint (1)
- magnesium (1)
- mesenchymal stem cells (1)
- osteoarthritis (1)
- osteogenic differentiation (1)
- osteogenic potential (1)
- perfusion bioreactor (1)
- pericytes (1)
- regenerative potential (1)
- scaffold (1)
- stemness (1)
- tissue engineering (1)
- vertebral body (1)
- vitamin D (1)
- vitamin D receptor (1)
- vitamin D3 (cholecalciferol, VD3) (1)
Institute
Sonstige beteiligte Institutionen
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (7) (remove)
EU-Project number / Contract (GA) number
- 607051 (1)
Active vitamin D (1,25(OH)2D3) is known to exert direct anti-cancer actions on various malignant tissues through binding to the vitamin D receptor (VDR). These effects have been demonstrated in breast, prostate, renal and thyroid cancers, which all have a high propensity to metastasise to bone. In addition, there is evidence that vitamin D catabolism via 24-hydroxylase (CYP24A1) is altered in tumour cells, thus, reducing local active vitamin D levels in cancer cells. The aim of this study was to assess VDR and CYP24A1 expression in various types of bone metastases by using immunohistochemistry. Overall, a high total VDR protein expression was detected in 59% of cases (39/66). There was a non-significant trend of high-grade tumours towards the low nuclear VDR expression (p = 0.07). Notably, patients with further distant metastases had a reduced nuclear VDR expression (p = 0.03). Furthermore, a high CYP24A1 expression was detected in 59% (39/66) of bone metastases. There was a significant positive correlation between nuclear VDR and CYP24A1 expression (p = 0.001). Collectively, the VDR and CYP24A1 were widely expressed in a multitude of bone metastases, pointing to a potential role of vitamin D signalling in cancer progression. This is of high clinical relevance, as vitamin D deficiency is frequent in patients with bone metastases.